A new trading day began on Tuesday, with Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock price up 0.67% from the previous day of trading, before settling in for the closing price of $20.88. ACAD’s price has ranged from $13.40 to $25.23 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -62.55%. With a float of $166.02 million, this company’s outstanding shares have now reached $167.12 million.
Considering the fact that the conglomerate employs 654 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 92.04%, operating margin of 23.58%, and the pretax margin is 26.58%.
Acadia Pharmaceuticals Inc (ACAD) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Acadia Pharmaceuticals Inc is 0.80%, while institutional ownership is 103.68%. The most recent insider transaction that took place on Jun 04 ’25, was worth 314,634. In this transaction Director of this company sold 14,446 shares at a rate of $21.78, taking the stock ownership to the 15,095 shares. Before that another transaction happened on Jun 04 ’25, when Company’s Director proposed sale 14,446 for $21.78, making the entire transaction worth $314,638.
Acadia Pharmaceuticals Inc (ACAD) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -62.55% per share during the next fiscal year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Here are Acadia Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.53. Likewise, its price to free cash flow for the trailing twelve months is 23.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.37, a number that is poised to hit 0.14 in the next quarter and is forecasted to reach 0.84 in one year’s time.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Compared to the last year’s volume of 2.27 million, its volume of 2.0 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 7.46%.
During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 64.41%, which indicates a significant increase from 11.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.76 in the past 14 days, which was lower than the 0.79 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.08, while its 200-day Moving Average is $17.62. Nevertheless, the first resistance level for the watch stands at $21.18 in the near term. At $21.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $21.51. If the price goes on to break the first support level at $20.85, it is likely to go to the next support level at $20.68. Should the price break the second support level, the third support level stands at $20.52.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats
With a market capitalization of 3.52 billion, the company has a total of 167,362K Shares Outstanding. Currently, annual sales are 957,800 K while annual income is 226,450 K. The company’s previous quarter sales were 244,320 K while its latest quarter income was 18,990 K.
